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SUMMARY 
A sensitive and selective high-performance liquidchromatographic assay for ibuprofen 
and its major metabolites in biological fluids is described_ To ensure good chromatographic 
separation the drug and metabolites were in on a gradient elution system and detected 
with a variable wavelength detector set at 220 nm. A second, more rapid, isocratic system 
is also described for the detection of only ibuprofen_ 
INTRODUCTLON 
Ibuprofen [ 2-(4-isobutylphenyl)propionic acid] is an orally administered, 
non-steroidal anti-inflammatory agent used extensively in the treatment of 
arthritis. The literature concerned with the biochemical and toxicological 
studies carried out in man and animals has been reviewed [l] _ The metab- 
olism of ibuprofen in man and several animal species is documented [2] _ 
Major metabolites in man are 2-[4-(2-hydroxy-2-methylpropyl)phenyl] - 
propionic acid (OH-ibuprofen). and 2-[4-(2-carboxypropyl)phenyll propionic 
acid (COOH-ibuprofen). Among the techniques employed to quantify ibu- 
profen and its metabolites in biological samples are paper chromatography [3], 
gas-liquid chromatography (GLC) with prior derivatization 141, GLC with 
electron capture detection [5], GLC-mass spectrometry combinations [6] 
and high-performance liquid chromatography (HPLC) [7-lo]_. To the authors’ 
knowledge all the HPLC assays reported for ibuprofen measure only the parent 
compound_ The ability to quantify metabolite levels in urine and plasma can 
greatly aid in drug metabolism- and pharmacokinetic studies. It was therefore 
considered appropriate to develop- an HPLC assay capable of detection of 
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ibuprofen and its major metabolites (Assay I)_ A second, more rapid assay for 
ibuprofen alone was also developed (Assay II). 
M_4TERIALS AND METHODS 
Standards 
Ibuprofen, OH-ibuprofen, COOH-ibuprofen, and methyl prednisolone were 
provided by the Upjohn Company (Kalamazoo, MI, U.S.A.). Tolmetin was 
provided by McNeil Laboratories (Fort Washington, PA, U.S.A.) 
HPLC appanzfus for the simultaneous determination of ibuprofen, OH- 
ibwwofen and COOH-ibuprofen in biological samples, Assay I 
Due to the more highly polar nature of the two metabolites relative to the 
parent compound, isocratic elution was found to be unsatisfactory and a 
gradient system had to be employed_ The apparatus used consisted of two 
Waters Model 6000A pumps (Waters Assoc., Milford, MA, U_S.A_) controlled 
by a Model 660 solvent programmer, a Waters variable wavelength detector 
set at 220 nm and an Omniscribe chart recorder (Houston Instruments). 
Separation was achieved with a prepacked Whatman column (Whatman, 
Clifton, NJ, U.S.A.) (25 cm X 4.5 mm I.D., Partisil 10 ODS-3 packing). The 
eiuents delivered by the two pumps were of the following compositions_ Eluent 
Ar acetonitrile-water (28:72)_ To each liter of eluent was added 500 yl of 
phosphoric acid and 500 ~1 of acetone_ Eluent B: acetonitrile-O-05 M mono- 
basic potassium phosphate (50:50). The delivery rate of the mobile phase 
was 2 ml mm-’ and a typical run was performed in the following manner. 
The column was allowed to come to equilibrium with eluent A. At time zero 
the sample wasloaded ontothecolumnthrough aWatersloopinjector_After8 
x-nin the solvent programmer was switched from these initial conditions to the 
‘Mm” mode_ Over the next 6 min (i.e. 8-14 min after the injection) the per- 
centage of eluent A in the eluting solvent was reduced from 100% to 0% in 
a linear manner with respect to time while the percentage of eluent B increased 
from 0% to 100%. Thus, from 14 min after the injection_ to the termination of 
the run the eluting solvent was 100% B. Fig. lc graphically represents the 
change in eluent composition with respect to time_ 
HPLC apparatus for the determination of ibuprofen in biological samples, 
Assay II 
The basic HPLC equipment used for Assay II was similar in all respects 
to that used in Assay 1. tlowever, due to the isocratic nature of the assay, the 
solvent delivery system consisted of a single pump_ The mobile phase was 
methanol-water (70:30) with 1 ml of phosphoric acid added to each liter of 
eluent. The mobile phase was delivered at a flow-rate of 2.5 ml min-’ . 
Sample preparation for Assay I 
Assay I was primarily used to assay urine samples for unchanged drug and 
metabolites. A simple clean-up extraction was required before urine samples 
could be chromatographed A l-ml sample of urine or diluted urine was ad&d 
to a screw-tipped test tube_ A 100~,cl aliquot of internal standard solution 
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(methylprednisolone 1 mg/ml) was added followed by 1 ml of 1.5 M hydro- 
chloric acid to reduce the pH below 1. Finally, 500 ~1 of water and 10 ml of 
methylene chloride were added and the tubes were capped and shaken for 20 
min. The tubes were then gently centrifuged (250 g, 3 min, Sorvall RC3 
centrifuge)_ The lower organic phase was transferred to a clean, dry test tube 
and was evaporated to dryness under a stream of prepurified nitrogen at 40°C. 
Samples were reconstituted with 200 ~1 of methanol and lo-30 ~1 of this 
were injected onto the column. 
To enable free and conjugated metabolites to be assayed in the urine, all 
samples were assayed twice. Free drug and metabolites were assayed as 
described above. Total drug and metaholites (free plus conjugated) were 
assayed following alkaline hydrolysis. Hydrolysis was carried out by incubating 
1 ml of urine or diluted urine with 500 ~1 of 1 M sodium hydroxide solution 
for 20 min at room temperature. Following this period the extraction was 
carried out as described above. 
Sample preparation for Assay II 
Assay II was primarily used to assay plasma samples for unchanged drug. 
Plasma samples were subjected to a clean-up extraction before being chroma- 
tographed. To 1 ml of plasma in a screw-topped test tube were added 100 ~1 
of internal standard soiution (tolmetin, 100 pg/ml internal standard solution). 
The samples was acidified with 500 ~1 of 1 M hydrochloric acid and 10 ml of 
methylene chloride were added_ The tubes were capped, shaken for 10 min and 
then centrifuged at 1000 g for 5 min to ensure complete phase separation. 
The lower, organic layer was transferred to a clean, dry test tube and was 
evaporated to dryness under a stream of prepurified nitrogen at 40°C. Just 
prior to analysis the residue was redissolved in 200 ,~l of Assay II eluent and 
lo-30 ~1 of this sample were loaded onto the column. 
Calibration procedure for Assay I 
Blank urine was spiked with ibuprofen, OH-ibuprofen and COOH-ibuprofen 
in the range 5-200 gg ml-’ _ The urine samples were subjected to the prepara- 
tion procedures described above and were chromatographed in the normal 
manner- Peak heights of ibuprofen, metabolites and internal standard were 
measured from the resultant chromatograms. A peak height ratio (peak height 
of compound divided by peak height of ‘internal standard) versus concentra- 
tion curve was constructed for the parent drug and metabolites. The peak 
height ratios of unknown samples were compared to this standard curve, cor- 
rections being made for any dilutions involved. 
Calibmtion procedure for Assay II 
Blank plasma was spiked with ibuprofen over the range l-140 pg/ml. Plasma 
prepared in this way was subjected to the normal extraction and chromato- 
graphic procedures. From the chromatograms obtained the ibuprofen:tolmetin 
peak height ratio was calculated and a calibration curve. relating this ratio to 
the plasma concentration of ibuprofen .was constructed. Unknown samples 
were quantified by reference to this standard curve. 
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RESULTS AND DISCUSSION 
-4 typical HPLC trace for Assay I is shown in Fig_ la_ The relative order of 
peak retention and retention times were: OH-ibuprofen (8.0 min), COOH- 
ibuprofen (10.2 min), methylprednisolone (13.6 min) and ibuprofen (21.8 
min). No interfering peaks were observed when blank urine was subjected to 
the assay (Fig_ lb)_ Calibration data (compound peak height ratio versus 
compound concentration, pg ml-‘) were best fitted by the power curve 
described by the equation 
lnY=Sln_x+lrD (I) 
where X and Y are concentration and peak height ratio, respectively. The 
relationship between X and Y was actually linear since S was essentially 
equal to unity. However, the use of eqn. 1 gave the lowest coefficient of 
variation of inversely estimated concentrations, apparently as a result of the 
different weighting of the points. The results of inversely estimating ibuprofen 
and metabolite concentrations from the calibration data generated from 
standards prepared over several months are shown in Table I. No systematic 
bias was observable over the concentration range studied. The intra-day re- 
producibility of Assay I is good, as is shown in Table II. Five independently 
prepared samples at three concentrations were run for each compound. The 
highest coefficient of variation (C-V.) observed was less than 1470, two other 
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Fig. 1. (a) A typical cbromatogram of ibuprofen and it& metabolites extracted from urine_ 
I = Injection; -4 = solvent front and highly polar contaminants; B = OH-ibuprofen; C = 
COOH-ibuprofen; D = metbylprednisolone; E = low polar contaminants; F = ibuprofen_ 
Blank urine (b) shows no interfering peaks. The change in eluent composition as a function 






IBUPROFEN, OH- AND COOH-MEPABOLITE 
FROM THE URINARY CALIBRATION CURVES 
Data presented in this table was collected over several months. Each inversely estimated 
concentration is the mean of at least 15 independently prepared caIibration points assayed 
















7-O 14-O 28-O 56-l 84-l 112-2 140-2 
102.2 98.9 100.6 105.5 98.6 93.7 107.6 
2.2 -1.1 0.6 5.5 -1.4 -7.3 7.6 
13.6 15-l 14-6 11.6 10.2 10.5 8.3 
9.1 18.3 36.6 73.2 109.7 146-3 184 
99.6 102.8 104-Q 104 98.7 92.2 106.7 
-0.4 2.8 4.9 4 -1.3 -7.8 6.7 
16.4 19.7 16.8 12.2 10.6 13.1 9.7 
9.3 18.6 37.2 74.5 111.7 149.0 186 
100.5 98.1 110.8 100.0 97.3 97.2 104.4 
0.5 -1.9 10.8 0 -2.7 -2.8 4.4 
18.6 14.5 20.7 9.01 11.0 17.7 10.4 
C.V. values were just greater than 10% while the remaining six were less than 
10%. Urine spiked with ibuprofen and metabolites at 30 pg/ml was divided 
into l-ml aliquots and frozen. On each assay day one urine aliquot was thawed 
and assayed_ The stability of frozen samples and the inter-day reproducibility 
is shown in Table III. No trend towards sample degradation is seen but, as may 
have been expected over such a protracted period of time, slightly larger 
coefficients of variation are observed. 
The lower limit of detection of Assay II as described for ibuprofen and its 
metabolites (around 5 pg ml-‘) was sufficient to enable detection of 1.0% 
of a 400-mg dose of ibuprofen in 1 1 of urine. For the purposes for which the 
assay was used this proved to be adequate. If greater sensitivity is desired, 
extraction from a larger urine volume, or a decrease in internal standard and 
injection of a larger volume of the final extract would prove satisfactory. 
A typical HPLC trace from Assay II is shown in Fig. 2a. The relative order 
of peak retention and retention times were tolmetin 3.2 min, and ibuprofen 
7.7 min. No interfering peaks in blank plasma were observed (Fig. 2b). Calibra- 
tion data were again fitted by a power curve described by eqn. 1. A summary 
of the calibration data obtained from 22 pooled calibration curves is 
summarized in Table IV. Again no systematic bias was noted over the 
concentration range studied_ The intra-day reproducibility of Assay II is good 
as assessed by. assaying six independently prepared plasma samples at three 
different concentrations (Table V). The coefficients of variation observed 
(all less than 10%) are of the same order as those reported by Keams and 
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TABLE II 
THE INTRA-DAY REPRODUCIBILITY OF ASSAY I 
Ezch peak height ratio was obtained from an independently prepared calibration sample; all 
sampies were assayed on the same day. 
OH-metaholite 
concentration (pglml) 
Peak height ratio 
Mean 2.83 1.20 0184 
c-v_ (a) 10.1 6.5 3.4 
COOH-metabolite 
concentration (flg/mI) 
Peak height ratio 
186 74.5 9.3 
2.08 0.876 0.150 
2.78 0.885 0.136 
2-09 0.886 0.137 
2.58 0.906 0.137 
2.18 0.808 0.117 
Mean 2.34 0.872 0.135 
C.V. (W) 13.5 4.3 8.7 
Ibuprofen 
concentration (pg/mI) 
Peak height ratio 
140 56.1 7.0 
2.83 1.19 0.134 
2.45 1.28 0.162 
2.74 1.09 0.158 
2.55 1.05 0.158 
2-95 0.999 0.147 
Mean 2-70 l-121 0.152 
c-v_ (%) 7.4 10.4 7.5 
183 73.2 9.1 
2.49 l-22 0.186 
2.87 1.30 0.182 
2-65 l-15 0.194 
2.88 1.20 0.179 
3.25 1.10 0.179 
TABLE III 
IXI’ER-D_4Y REPRODUCIBILITY OF ASSAY I AS INDICATED .%Y QUALITY 
CONTROL SAMPLES 
OH-Ibuprofen COOH-Ibuprofen Ibuprofen 
Theo- &g/ml) 36.6 37.2 28.0 
Range (rg/ml) 31.8-41.3 28.9-42-O 21.9-37.6 
Mean (pg/ml) 36.5 36.8 28.2 
SD. (5) 3.1 4.0 4-9 
C_V.(%) 8.4 10.8 17.3 
Wilson [IO) although the range of concentrations reported here is much 
greater_ Plasma spiked with ibuprofen at 30 pg/ml was divided into l-ml 
aliquots and frozen. On each assay day one of these quality contr@ sampies 
was thawed and assay&_ The results are presented in Table VI_ The low 
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Fig. 2. (a) A typical chromatogram of ibuprofen extracted from plasma_ I = Injection; A = 
solvent front and highly polar contaminants; B = toJmetin;C = ibuprofen_ Blank plasma (b) 
showed no interfering peaks. 
TABLE IV 
PERCENTAGE OF THEORETICAL IBUPROFEN CONCENTRATION ESTIMATED 
FROM STANDARD CURVES FROM ASSAY II 
Data summarized in this table were coliected over several months. Each inversely estimated 
mean is the result of at least 22 independently prepared calibration points assayed over this 
time span. 
Ibuprofen 
concentration (j~g/ml) 1-4 2-8 7-O 14.0 42.1 105 140 
Mean (96) 106 95-7 105.9 100-3 98.1 101.5 100.4 
Bias (96) 6 -4.3 5.9 0.3 -1.9 1.5 0.4 
c-v. (%) 21-l 139 14.8 13.6 7.4 11.3 5-8 
TABLE V 
THE INTRA-DAY REPRODUCIBDXTY OF ASSAY I 
Each peak height ratio was obtained from independently prepared samples; all samples were 
assayed on the same day_ 
Ibuprofen 
concentration @g/ml) 
Peak height ratio 
140 14 2.8 
10.53 1.39 0.253 
10.20 1.36 0.264 
1011 1.38 O-258 
11.36 140 0.273 
11-48 l-17 0.281 
10.97 1.11 0.279 
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TABLE VI 
INTER-D-AY REPRODUCIBIISrY OF ASSAY II AS INDICATED BY QUALITY 
CONTROL SAMPLES 
Theory (wlmi) 30 
Range (riz/ml) 25-9-34-4 
Mean (gg/ml) 29.1 
SD_ (5%) 3.3 
c-v. (a) 11.3 
coefficient of variation (11.3%) indicates good stability of frozen plasma 
sampIes and reproducibility of the assay over several months. 
The applicability of the assays reported in a clinical study has been demon- 
strated. Fig. 3a presents the mean plasma concentration-time curves obtained 
iin ix3 iiD iiB 
“8-- “8- oo- “8- 
0 0 uo 0 
o-6 o-12 O-2” O-18 
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Fig_ 3. A demonstration of the applicability of Assays I and II to pharmacokinetic studies. 
(a) PIasma concentratiorr-time curve of ibuprofen after oral administration of a 400-mg 
tablet- (Each point is the mean of 15 subjects.) (b) CumuIative percentage of ibuprofen and 
its two major metabolites excreted in the urine after a 400-mg dose of ibuprofen. The larger 
bars represent the total percentage excreted in the measuring period. The smaller, shaded 
bars represent the percentage of fi-ee drug or metabolite excreted in the same interval. (All 
values are the means of 15 subjects.) 
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from 15 subjects after a 400-mg dose of ibuprofen orally_ Assay II as reported 
here was ideally suited for following these plasma profiles since the concentra- 
tion range encUuntered over the study was 110-l pg/ml_ It was generally con- 
sidered to be u~ecessary to lower the assay limits; however, since only about 
l/lOth of the reconstituted sample was injected on column the theoretical 
limits of the assay as described could easily be reduced to 0.1 pg/ml, thus 
making this assay comparable to or better than that of Ali et al_ [9] _ 
Urinary excretion data from the same study are presented in Fig. 3b to 
demonstrate the applicability of Assay I_ Urinary recovery as assayed by this 
new HPLC method is in good agreement with literature values. It should he 
noted that Assay I is .applicable to plasma samples but that the concentrations 
of metabolite present are nearly always at the limits of detection. 
CONCLUSION 
Assays have been developed to quantify ibuprofen or ibuprofen and its 
major metabolites in biological fluids. Adequate sensitivity and reproducibility 
of calibration data have been demonstrated_ The applicability of the described 
assay methods has been shown. In future papers the applications of these 
assays to biological samples (plasma and urine) obtained in a four-phase 
clinical study involving ibuprofen wiil he discussed_ 
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